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Recent studies have suggested that epigenetic inactivation of tumour-related genes by promoter methylation participates in the
development of gastric cancer. We newly identified the frequently aberrant promoter methylation of alpha-1B-adrenergic receptor
(ADRA1B) in colorectal cancer by methylation-sensitive representational difference analysis (MS-RDA) and examined the methylation
status of the ADRA1B promoter in 34 paired samples of colorectal cancer and surrounding epithelial tissue, and 34 paired samples of
gastric cancer and surrounding epithelial tissue. In colorectal cancers, only four of 34 (11.8%) tumours showed ADRA1B promoter
methylation. In contrast, ADRA1B promoter methylation was detected in 24 of 34 (70.6%) gastric cancers and in 14 of 34 (41.2%)
surrounding epithelial tissues. The frequency of ADRA1B promoter methylation was higher in gastric epithelial tissues with intestinal
metaplasia (41.6%) than in those without intestinal metaplasia (25.0%). Reverse transcription–PCR detected reduced ADRA1B
expression in 12 of 18 (66.7%) gastric cancers, and its promoter methylation was detected in 11 of these 12 (91.7%) gastric cancers
with reduced ADRA1B expression. Thus, ADRA1B promoter is frequently methylated in gastric cancer. Our results suggest that the
ADRA1B gene is an important tumour-related gene frequently involved in the development and progression of gastric cancer.
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Aberrant DNA methylation is a feature of human cancers,
characterised by generalised hypomethylation and regional
hypermethylation (Gama-Sosa et al, 1983; Feinberg et al, 1988).
When regional hypermethylation occurs in CpG sites within the
promoter region of tumour-suppressor genes or tumour-related
genes that normally are unmethylated, gene transcription is
inhibited, similar to the effects of mutations and deletions
(Herman et al, 1994; Merlo et al, 1995; Baylin and Herman,
2000; Esteller et al, 2001). There is a growing list of tumour-
suppressor genes or tumour-related genes associated with CpG
island methylation in cancers (Leung et al, 1999; Kang et al, 2000;
Shim et al, 2000; Kaneda et al, 2002a,b; Li et al, 2002; Byun et al,
2003; Chan et al, 2003; Tokumaru et al, 2003; Choi et al, 2004;
Miotto et al, 2004).
Gastric cancer is the leading cause of cancer-related mortality
in Japan and many other countries (Fuchs and Mayer, 1995).
Although the molecular genetics of gastric cancer remain unclear,
accumulating evidence suggests that many tumour-suppressor
genes and tumour-related genes are inactivated by promoter
methylation (Leung et al, 1999; Kang et al, 2000; Shim et al, 2000;
Kaneda et al, 2002a,b; Li et al, 2002; Byun et al, 2003; Chan et al,
2003; Tokumaru et al, 2003; Choi et al, 2004; Miotto et al, 2004).
Among various genes, methylation in the CpG island of the hMLH1
gene, which encodes for the DNA mismatch repair protein MLH1,
has been linked to a substantial proportion of sporadic gastric
cancers with microsatellite instability (Fleisher et al, 1999; Leung
et al, 1999). Some gastric cancers are characterised by a high
degree of concordant methylation of CpG islands, including p16,
E-cadherin, and hMLH1; such tumours are classified as high
CpG island methylator phenotype (CIMP) (Toyota et al, 1999).
Epigenetic inactivation of tumour-related genes by promoter
methylation thus seems to have an important role in the
development of gastric cancer.
To enable a genome-wide search for differences in CpG
methylation between cancer and normal tissue, methylation-
sensitive representational difference analysis (MS-RDA) was
developed by Ushijima et al (1997). This method demonstrated
reduced expression of the INSIG1 gene and possible silencing of
the p41Arc gene due to promoter methylation in gastric cancer
(Kaneda et al, 2002a). In addition, several genes were also shown to
be inactivated by aberrant promoter methylation in human
cancers (Takai et al, 2001; Kaneda et al, 2002b; Asada et al,
2003). In this study, we used the MS-RDA technique to analyse
two human colorectal cancers and newly identified alpha-1B-
adrenergic receptor (ADRA1B). In colorectal cancers, only a subset
of tumours showed aberrant ADRA1B promoter methylation. In
contrast, ADRA1B promoter methylation was found much more
frequently not only in gastric cancers but also in their surrounding
epithelial tissues, and the majority of gastric cancers with ADRA1B
promoter methylation had reduced ADRA1B expression. Our
results suggest that aberrant ADRA1B promoter methylation with a
consequent reduction in ADRA1B expression may be involved in
gastric carcinogenesis.
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Clinical materials
Thirty-four paired samples of colorectal cancer and surrounding
epithelial tissue, and 34 paired samples of gastric cancer and
surrounding epithelial tissue were obtained at the time of surgery
with informed consent. In addition, three samples of gastric
epithelial tissue free of gastric cancer were obtained from the
patients who underwent pancreaticoduodenectomy for the treat-
ment of pancreatic cancer. Samples were immediately frozen
in liquid nitrogen and stored at  801C until DNA and RNA
extraction. Among the 34 samples of surrounding gastric epithelial
tissue, intestinal metaplasia (IM) was found in 26 (76.5%) on
histopathological examination.
Mmethylation-sensitive representational difference
analysis, sequencing, and database search
Methylation-sensitive representational difference analysis was
performed as described by Ushijima et al (1997), using DNA
obtained from two paired samples of colorectal cancer and
surrounding epithelial tissue. Briefly, genomic DNAs of cancer
and surrounding epithelial tissue were digested by HpaII (New
England Biolabs, Beverly, MA, USA), and the Rhpa adaptor was
ligated to the digest. HpaII-amplicon was prepared by PCR. The
Rhpa adaptor of the HpaII-amplicon from the corresponding
sample of normal tissue was removed by MspI digestion, gel-
purified (Gel Extraction Kit; Qiagen, Hilden, Germany), and
switched to JHpa adaptor. The HpaII-amplicon from the
surrounding epithelial tissue was mixed with an excess amount
of that from cancer tissue to perform competitive hybridisation,
followed by PCR with JHpa primer. After two cycles of competitive
hybridisation, the products were cloned into pGEM-T Easy vector
(Promega, Madison, WI, USA). Then, plasmid DNA was cycle
sequenced with the SP6 and T7 primers, using a CEQ Dye
Terminator Cycle Sequencing Quick Start Kit (Beckman Coulter,
Inc., Fullerton, CA, USA), and a CEQ2000XL DNA analyser
(Beckman Coulter, Inc.). Homology searches were performed with
BLAST program at the GenBank web site.
Methylation-specific PCR for ADRA1B promoter in
colorectal and gastric cancers and surrounding epithelial
tissues
We performed methylation-specific PCR (MSP) to determine the
methylation status of ADRA1B promoter in 34 paired samples of
colorectal cancer and surrounding epithelial tissue and 34 paired
samples of gastric cancer and surrounding epithelial tissue, using
bisulphite-modified genomic DNA as described by Herman et al
(1996). In brief, 1mg of DNA was denatured by NaOH and
modified by sodium bisulphite. The DNA sample was then purified
with Wizard DNA purification resin (Promega Corp.), treated
again with NaOH, ethanol precipitated, and resuspended in H2O.
We used four primer sets (Region 1, nucleotides  590 to  506;
Region 2, nucleotides  517 to  274; Region 3, nucleotides  323 to
 213; and Region 4, nucleotides  225 to  61) to comprehensively
investigate the methylation status of ADRA1B promoter (nucleo-
tides  754 to þ173) (Ramarao et al, 1992). Because Region 2
includes a very wide area, which contains many CpGs, we set MSP
for Region 3, which extensively overlaps with the 30 end of the
Region 2. The transcription start site was defined as þ1, and the
primer sets and PCR conditions are described in Table 1. Human
genomic DNA treated in vitro with SssI methylase (New England
Biolabs, Inc, Beverly, MA, USA) was used as positive control. The
PCR products were analysed on 2% agarose gels with ethidium
bromide and visualised under UV illumination. The presence of a
visible PCR product in sets for methylated specific DNA was
judged to be methylation-positive.
Bisulphite sequencing of ADRA1B promoter in gastric
cancers and surrounding epithelial tissues
We performed bisulphite sequencing of ADRA1B promoter in 10
randomly selected paired samples of gastric cancer and surround-
ing epithelial tissue. Bisulphite-modified DNA was used for PCR
with primers common for methylated and unmethylated DNA
sequences, which amplified a product containing 68 CpG sites
(nucleotides  672 to  59) in ADRA1B promoter. The primer sets
and PCR conditions are described in Table 2. The PCR products
were gel-purified (Gel Extraction Kit; Qiagen, Hilden, Germany)
Table 1 Primer sets and PCR conditions of methylation-specific PCR for ADRA1B promoter
Sense primer Antisense primer Amplicon size (bp) Annealing temperature (1C) Cycles
Region 1
(M) GGGTGATTCGCGATTTTTAC CTCCCAAATCACCTCTACGA 83 56 40
(U) GTGGGTGATTTGTGATTTTTATGT CTCCCAAAATCACCTCTACAAA 85 56 40
Region 2
(M) CGTTTAAGGTTCGTTTTCGC AAAAAAATCTACTTCAATAAACCGCT 243 56 40
(U) TTATGTTTAAGGTTTGTTTTTGTGG AAAAAATCTACTTCAATAAACCACT 245 54 40
Region 3
(M) TGGATTCGTATTGTTTTTTAGTGTC AAAAAATCTACTTCAATAAACCGCT 110 58 35
(U) TTGGATTTGTATTGTTTTTTAGTGTGTTG AAAAAATCTACTTCAATAAACCACT 111 58 35
Region 4
(M) AAGTAGATTTTTTTCGGCGTTC AACTCCAAATTTAATAATCCACGTC 165 60 35
(U) AGTAGATTTTTTTTGGTGTTTGT AACTCCAAATTTAATAATCCACATC 165 60 35
(M)¼methylated DNA specific; (U)¼unmethylated DNA specific; ADRIB¼alpha-1B-adrenergic receptor;P C R¼polymerase chain reaction.
Table 2 Primer set and PCR conditions of bisulphite sequencing for ADRA1B promoter
Sense primer Antisense primer Amplicon size (bp) Annealing temperature (1C) Cycles
TATTAAAGGTAAGTAGTTTTTAATTTATTT ACAACTCCAAATTTAATAATCCAC 614 58 40
ADRA1B¼alpha-1B-adrenergic receptor;P C R¼polymerase chain reaction.
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recombinants were cycle sequenced with the SP6 and T7 primers,
using a CEQ Dye Terminator Cycle Sequencing Quick Start Kit and
a CEQ2000XL DNA analyser (both from Beckman Coulter, Inc.).
The methylation status of each CpG site was determined by
sequencing, as unmethylated cytosines are converted into
thymines by bisulphite treatment, whereas methylated cytosines
remain unaltered.
Semiquantitative reverse transcription(RT)–PCR
Total RNA was prepared from 18 paired samples of gastric cancer
and surrounding epithelial tissue for which the methylation status
of ADRA1B promoter had been assessed by MSP. The total RNA
was immediately treated with DNase I (Life Technologies, Rock-
ville, MD, USA) and reverse-transcribed using a Superscript III
reverse transcriptase kit (Life Technologies) to prepare first-strand
cDNA. A b-actin fragment was amplified as an internal control.
The primer set and PCR conditions are described in Table 3.
5q loss of heterozygosity analysis
5q loss of heterozygosity (LOH) analysis was carried out using a
single-nucleotide polymorphism (SNP) in the ADRA1B gene
(5q23–q32), three SNPs in the adenomatous polyposis coli gene
(5q21–q22), and an SNP in the interferon regulator factor-1 gene
(5q31.1) for the 18 paired samples of gastric cancer and
surrounding epithelial tissue examined by RT–PCR. Detailed
information about these five SNPs is available from JSNP (http://
snp.ims.u-tokyo.ac.jp). Sequence change in SNP from the PCR
product of surrounding epithelial tissue to that from the cancer
tissue was judged as 5q LOH positive. The primer sets and PCR
conditions are described Table 4; the primers for PCR were used as
sequence primers.
Statistical analysis
The Fishers’ exact test and Student’s t-test were used to examine
associations between two categorical variables. The level of
statistical significance was set at Po0.05.
RESULTS
Isolation of DNA fragments aberrantly methylated in
colorectal cancer
DNAs from two paired samples of colorectal cancer and
surrounding epithelial tissue were used as tester and driver for
MS-RDA. We obtained 33 DNA fragments by MS-RDA, and the
genomic origins of the 33 DNA fragments were analyssed by
sequencing and a GenBank database search. One DNA fragment
matched the promoter of the ADRA1B gene, which is located in
5q23–q32.
ADRA1B promoter methylation in colorectal and gastric
cancers and surrounding epithelial tissues
As shown in Figure 1A, ADRA1B promoter methylation was
detected by MSP in four of 34 (11.8%) colorectal cancers. In all
four of these colorectal cancers, methylation was limited to Region
3 and Region 4 in ADRA1B promoter. In contrast, no ADRA1B
promoter methylation was detected in the 34 corresponding
samples of normal colorectal epithelial tissue. Thus, ADRA1B
promoter methylation was a cancer-specific event in the colorectal
cancers and surrounding epithelial tissues.
As shown in Figure 1B, ADRA1B promoter methylation was
detected in 24 of 34 (70.6%) gastric cancers and in 14 of 34 (41.2%)
surrounding epithelial tissues. Alpha-1B-adrenergic receptor
promoter methylation in gastric cancers and in surround epithelial
tissues showed no significant correlation with clinicopathological
characteristics such as age and gender of the patients or the
location, stage, and differentiation of their tumours. Alpha-1B-
adrenergic receptor promoter methylation was not detected in the
three samples of gastric epithelial tissue obtained from patients
with pancreatic cancer unassociated with gastric cancer. Among
the 34 gastric cancers, ADRA1B promoter methylation was
detected in Region 1 in 12 cancers (35.3%), Region 2 in 14
(41.2%), Region 3 in 18 (52.9%), and Region 4 in 23 (67.6%).
Therefore, in gastric cancers, the frequencies of ADRA1B promoter
methylation increased progressively from Region 1 to Region 4.
Among the 34 surrounding epithelial tissues, ADRA1B promoter
methylation was detected in Region 1 in four samples (11.8%),
Region 2 in three (8.8%), Region 3 in four (11.8%), and Region 4 in
Table 3 Primer set and PCR conditions of RT–PCR for ADRA1B expression
Sense primer Antisense primer Amplicon size (bp) Annealing temperature (1C) Cycles
GCTAAGACGTTGGGCATTGT GTTGAAGTAGCCCAGCCAGA 144 60 35
ADRA1B¼alpha-1B-adrenergic receptor;P C R¼polymerase chain reaction; RT¼reverse transcription.
Table 4 Primer sets and PCR conditions for the region including SNP in ADRA1B, APC, and IRF-1
Sense primer Antisense primer
Amplicon
size (bp)
Annealing
temperature (1C) Cycles
ADRA1B (JSNP ID; IMS-JST087433: A4154019G)
CTGGTCACGCGGAGGAAG GGTTCTTGGTGGTTCTCTTTGG 244 60 35
APC (JSNP ID; IMS-JST061883: C113263G)
TGCTTGAAAATTCCAGTGTCA GGACATTTTTGACCGCAGTT 382bp 62 35
APC (JSNP ID; IMS-JST041076: A14531742C,
and JSNP ID; IMS-JSTO41075: G14531786A)
GCCAGGATATGGAAAAACGA TTCCAAGGCAGAACAGAACA 255bp 62 35
IRF-1 (JSNP ID; IMS-JST005685: T34238200C)
ATCAGCAGCCAGAGGGTAGA CTGGCAAAAGCATCTGTGAA 231bp 62 35
ADRA1B¼alpha-1B-adrenergic receptor;P C R¼polymerase chain reaction.
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methylation was lower in the surrounding epithelial tissues than
in the cancers; however, similar to the cancers, the frequency of
ADRA1B promoter methylation was highest in Region 4 in the
surrounding epithelial tissues.
When we analysed the correlations between ADRA1B promoter
methylation and the presence of IM in surrounding epithelial
tissues, ADRA1B promoter methylation was detected in 12 of 26
(46.2%) gastric epithelial tissues with IM and in two of eight
(25.0%) gastric epithelial tissues without IM (Figure 2). The
frequency of ADRA1B promoter methylation was slightly but not
significantly higher in gastric epithelial tissues with IM than in
gastric epithelial tissues without IM.
In 10 analysed gastric cancers, the results of bisulphite
sequencing of ADRA1B promoter methylation were concordant
with those of MSP regarding the extent of the methylation area
(Figure 3A and B). Four of 10 samples judged to be methylation-
negative on MSP showed sequence changes of nearly all cytosines
to thymines in eight recombinants in the ADRA1B promoter on
bisulphite sequencing. Six of 10 samples judged to be methylation-
positive on MSP exhibited methylation in nearly all eight
recombinants in the same region. Seven of 10 analysed samples
of surrounding epithelial tissue judged to be methylation-negative
on MSP showed sequence changes of nearly all cytosines to
thymines in eight recombinants in the ADRA1B promoter on
bisulphite sequencing, similar to Case 7. In three of 10 samples of
surrounding epithelial tissues judged to be methylation-positive in
Region 4 on MSP, bisulphite sequencing showed sequence changes
of nearly all cytosines to thymines in eight recombinants in the
ADRA1B promoter, similar to Case 5. In most gastric cancers
positive for ADRA1B promoter methylation, the band of PCR
products obtained with sets for methylated specific DNA was more
intense than that obtained with sets for unmethylated specific
DNA, similar to Case 5 and Case 7 (Figure 3A). In some of the
corresponding epithelial tissues positive for ADRA1B promoter
methylation, the band of PCR products obtained with sets for
methylated specific DNA was less intense than that obtained with
sets for unmethylated specific DNA, similar to Case 5 (Figure 3A).
Therefore, even in samples judged to be methylation-positive, the
quantity of methylated DNA was less than that of unmethylated
DNA in the surrounding epithelial tissues, and this difference may
account for the inconsistency between the results of MSP and
bisulphite sequencing for the surrounding epithelial tissues.
Correlation among reduced ADRA1B expression, ADRA1B
promoter hypermethylation, and 5q LOH in gastric cancers
and surrounding epithelial tissues
Semiquantitative RT–PCR detected reduced ADRA1B expression
in 12 of 18 (66.6%) gastric cancers and three of 18 (16.4%)
surrounding tissues (Figure 4). Table 5 shows correlations among
ADRA1B promoter methylation status according to region, 5q
LOH, and ADRA1B expression in 18 paired samples of gastric
cancer and surrounding epithelial tissue. All three cases with
reduced ADRA1B expression in surrounding epithelial tissue also
had reduced ADRA1B expression in their corresponding cancers.
Eleven of 12 (91.7%) gastric cancers and three of three (100.0%)
corresponding tissues with reduced ADRA1B expression also had
promoter methylation in Region 2 and/or Region 3, and three of 11
(27.3%) gastric cancers with reduced ADRA1B expression also had
5q LOH. On the other hand, three gastric cancers and six
surrounding epithelial tissues with ADRA1B promoter methylation
did not have reduced ADRA1B expression. In most of these tissue
samples, ADRA1B promoter methylation was limited to Region 1
and/or Region 4, and no methylation was found in either Region 2
or Region 3. Thus, although one of 12 (8.3%) gastric cancers
with reduced ADRA1B expression had no ADRA1B promoter
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Figure 1 Alpha-1B-adrenergic receptor promoter methylation was
detected in four of 34 (11.8%) colorectal cancers and was not detected
in surrounding colorectal epithelial tissues. Alpha-1B-adrenergic receptor
promoter methylation was thus considered a cancer-specific event in
colorectal cancers and surrounding epithelial tissues. In contrast, ADRA1B
promoter methylation was detected in 24 of 34 (70.6%) gastric cancers and
in 14 of 34 (41.2%) surrounding epithelial tissues. In gastric cancers, the
frequency of ADRA1B promoter methylation increased progressively from
Region 1 to Region 4. In surrounding epithelial tissues, the frequency of
ADRA1B promoter methylation was also highest in Region 4.
46.2%
25.0%
IM + (n=26) IM – (n=8)
NS
Figure 2 The frequency of ADRA1B promoter methylation in gastric
epithelial tissues with IM (41.6%) was slightly but not significantly higher
than that in gastric epithelial tissues without IM (25.0%).
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expression had promoter methylation and 5q LOH; methylation
in Region 2 and Region 3 strongly correlated with inactivation of
ADRA1B expression.
DISCUSSION
We applied the MS-RDA method to two paired samples of
colorectal cancer and surrounding epithelial tissue, and identified
Case 5. A
B
Case 7.
Region 1
2
3
4
MU M U M U M U
MU M U M U M U
MU M U M U M U
MU M U M U M U
Cancer
Surrounding
epithelial tissue Cancer
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4
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7
8
1
2
3
4
5
6
7
8
1
2
3
4
5
6
7
8
1
2
3
4
5
6
7
8
Case 5.
Case 7.
Cancer
Surrounding epithelial tissue
Cancer
Surrounding epithelial tissue
Figure 3 Methylation status of ADRA1B promoter was analysed by methylation-specific PCR (MSP) and bisulphite sequencing of 68 CpG sites in eight
clones obtained by PCR of bisulphite-modified DNA. (A) Representative results of MSP for two paired samples of gastric cancer and surrounding epithelial
tissue. The presence of a visible PCR product in the lanes marked M indicates the presence of methylated alleles (black arrow). (B) Schemas of the results of
bisulphite sequencing of the same samples as those analysed by MSP. Unmethylated and methylated cytosines are shown by open and closed circles,
respectively. In Case 5, analysis of DNA from cancer tissue showed ADRA1B promoter methylation in Regions 1, 2, 3, and 4 on MSP and widespread
methylation in seven of eight clones on bisulphite sequencing. In Case 7, analysis of DNA from cancer tissue showed ADRA1B promoter methylation in
Regions 3 and 4 on MSP; methylation in these regions was also revealed by bisulphite-sequencing in six of eight clones. These two cases of cancer also had
reduced ADRA1B expression. In Case 7, analysis of DNA from the surrounding epithelial tissues showed no ADRA1B promoter methylation in any region on
MSP; similar results were obtained on bisulphite sequencing. In Case 5, analysis of DNA from the surrounding epithelial tissues showed methylation in Region
4 on MSP, but no methylation in any clone on bisulphite sequencing. In these two cases, the surrounding epithelial tissues showed no reduced ADRA1B
expression. Although DNA was judged to be methylation-positive in the surrounding epithelial tissues of Case 5, the amount of methylated DNA was
probably much less than that of unmethylated DNA, resulting in no apparent methylation on bisulphite sequencing.
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subset of colorectal cancers, but not in corresponding epithelial
tissues, suggesting that such methylation is a cancer-specific event
during colorectal carcinogenesis. Furthermore, in gastric cancers,
the ADRA1B promoter was very frequently methylated, generally
in association with reduced ADRA1B expression. Alpha1-adrenergic
receptors are members of the superfamily of G protein-coupled
receptors and mediate effects related to the regulation of cellular
hypertrophy and proliferation (Cruise et al, 1985; Lefkowitz and
Caron, 1988; Cotecchia et al, 1990; Thonberg et al, 1994; Spector
et al,1 9 9 7 ) .T h r e ed i s t i n c ts u b t y p e so falpha1-adrenergic receptors
(alpha1A- (ADRA1A), alpha1B- (ADRA1B), and alpha1D- (ADRA1D)
adrenergic receptors) have a prominent role in cell growth, and
activation of ADRA1A and ADRA1B inhibits serum-prompted cell
proliferation (Auer et al, 1998; Shibata et al, 2003). ADRA1B can
activate the cyclin-dependent kinase inhibitors p27KIP1 and
p21Cip1/WAF1, thereby inhibiting cell proliferation through this
pathway (Auer et al, 1998; Shibata et al, 2003). Reduced ADRA1B
expression might thus disrupt this pathway, giving cells aberrant
growth advantage.
Our results first demonstrated ADRA1B promoter methylation
in colorectal and gastric cancers. Alpha-1B-adrenergic receptor
promoter methylation was particularly frequent in gastric cancers,
whereas it was infrequent in colorectal cancers. Kim et al (2004)
reported that 60% of gastric cancer cell lines and 64% of gastric
cancers were methylated at the RUNX3 promoter, while RUNX3
promoter methylation was detected in only 4.9% colorectal
cancers. Thus, the frequency of promoter methylation of a given
tumour suppressor gene appears to vary among different types of
cancer. Our results suggest that ADRA1B promoter methylation
plays an important role in gastric cancer, but not in colorectal
cancer, similar to RUNX3 promoter methylation. Furthermore,
RT–PCR detected reduced ADRA1B expression in 12 of 18 (66.7%)
gastric cancers, 11 (91.7%) of which concurrently had ADRA1B
promoter methylation in Region 2 and/or Region 3. These results
clearly suggested that ADRA1B promoter methylation is the
principal mechanism for gene inactivation, with methylation of
Region 2 and Region 3 ( 517 to  213 relative to the transcription
start site) in the promoter being especially critical. Three of 11
(27.3%) gastric cancers with reduced ADRA1B expression also had
5q LOH. Therefore, 5q LOH is apparently related to reduced
ADRA1B expression in a subset of gastric cancers.
We also demonstrated that ADRA1B promoter methylation
occurred in the surrounding epithelial tissues of gastric cancers, a
small fraction of which concurrently had reduced ADRA1B
expression. Several studies have shown that promoter methylation
of multiple tumour-related genes is present in gastric epithelial
tissues with or without cancer, and that accumulations of such
genes promote gastric carcinogenesis (Leung et al, 1999; Kang
et al, 2000; Kang et al, 2001, 2003a,b; To et al, 2002; Waki et al,
2002; Chan et al, 2003). Waki et al (2002) reported that among 94
samples obtained from patients with gastric cancer, promoter
methylation of E-cadherin, hMLH1, and p16 was found in 67, 24,
and 44% of the surrounding gastric epithelial tissues, respectively.
Kang et al (2003a) reported that among 268 samples obtained from
gastric epithelial tissues without cancer, promoter methylation of
DAP-kinase, E-cadherin, THBS1, TIMP3, p14, MGMT, p16, COX2,
GSTP1 hMLH1, and RASSF1A was observed in 53.7, 41.0, 37.7, 23.1,
18.7, 10.9, 10.0, 4.1, 3.4, 1.7, and 0.4%, respectively. Our results
demonstrated that ADRA1B promoter methylation was present in
14 of 34 (41.2%) surrounding epithelial tissues of gastric cancers;
this frequency was similar to those of the important tumour-
related genes mentioned above. Kang et al (2003b) also
ADRA1B
-Actin
Case 1
Epithelial
Tissue Cancer
Epithelial
Tissue Cancer
Case 2
Figure 4 ADRA1B expression in gastric cancers was examined by RT–
PCR. In this series, samples of cancer tissue from Case 1 and Case 2 and
samples of surrounding epithelial tissue from Case 1 had markedly reduced
ADRA1B expression as compared with that of the surrounding epithelial
tissue of Case 2. As shown in Table 5, the samples of cancer tissue from
Case 1 and Case 2 and of surrounding epithelial tissue from Case 1
exhibited ADRA1B promoter methylation in Region 2 and/or Region 3. No
ADRA1B promoter methylation was found in the surrounding epithelial
tissue of Case 2.
Table 5 Correlation among ADRA1B promoter methylation
a, 5q LOH, and ADRA1B
Cancer Surrounding epithelial tissue
Case region 1 2 3 4 Expression 5q LOH Case region 1 2 3 4 Expression
1 M U M M Down Negative 1 U U M M Down
2 U M M U Down Negative 2 U U U U Normal
3 U U U M Normal Negative 3 U U U M Normal
4 U U U U Normal Negative 4 U U U U Normal
5 M M M M Down Negative 5 U U U M Normal
6 U M U U Down Positive 6 U U U U Normal
7 U U M M Down Negative 7 U U U U Normal
8 U U U M Normal Negative 8 U U U U Normal
9 M M M M Down Negative 9 M M M M Down
10 U U U U Normal Negative 10 U U U U Normal
11 U U U U Normal Negative 11 U U U U Normal
12 U M M M Down Negative 12 U U U M Normal
13 M M M M Down Negative 13 U M M M Down
14 U U U M Normal Negative 14 U U U U Normal
15 U U U U Normal Negative 15 U U U U Normal
16 M M M U Down Positive 16 U U U U Normal
17 U U M M Down Positive 17 U U U U Normal
18 M U U M Normal Negative 18 U U M M Normal
Expression in 18 paired samples of gastric cancer and surrounding epithelial tissue.
aMethylation status of the ADRA1B promoter in each region is represented as M or U. M
indicates methylation-positive, and U indicates methylation-negative (unmethylated). ADRA1B¼alpha-1B-adrenergic receptor;L O H¼loss of heterozygosity.
ADRA1B in gastric cancer
H Noda et al
388
British Journal of Cancer (2007) 96(2), 383–390 & 2007 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sdemonstrated that the average number of methylated genes
markedly increases from non-neoplastic mucosa to intestinal-type
gastritis. Although still controversial, the precancerous nature of IM
has been suggested by the clinical phenomenon that gastric
cancer often arises from intestinal-type gastritis. Although
the difference did not reach statistical significance, the frequency
of ADRA1B promoter methylation in surrounding epithelial
tissues with IM was higher than that in surrounding
epithelial tissues without IM. Thus, ADRA1B promoter methyla-
tion may also participate in the early phase of gastric carcino-
genesis, similar to the other tumour-related genes mentioned
above (Stemmermann, 1994). The degree of promoter methylation
and the frequency of reduced ADRA1B expression in cancer are
more extensive and more frequent than those in the surrounding
epithelial tissues. With gastric carcinogenesis, ADRA1B promoter
methylation spreads extensively, leading to reduced ADRA1B
expression. Such reduced expression gives cell aberrant growth
potential, resulting from loss of the growth inhibitory activity
of ADRA1B.
In conclusion, our study showed that ADRA1B promoter is
aberrantly hypermethylated in colorectal and gastric cancers. In
gastric cancer, ADRA1B promoter methylation occurs frequently
in both cancer tissue as well as in surrounding epithelial
tissue. Our results suggest that ADRA1B is an important tumour-
related gene with key roles in the development and progression of
gastric cancer.
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